Nothing Special   »   [go: up one dir, main page]

EA201992595A1 - Усиление фармакокинетики бифункциональных хелатов и их применения - Google Patents

Усиление фармакокинетики бифункциональных хелатов и их применения

Info

Publication number
EA201992595A1
EA201992595A1 EA201992595A EA201992595A EA201992595A1 EA 201992595 A1 EA201992595 A1 EA 201992595A1 EA 201992595 A EA201992595 A EA 201992595A EA 201992595 A EA201992595 A EA 201992595A EA 201992595 A1 EA201992595 A1 EA 201992595A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmacokinetics
strengthening
application
bifunctional chelates
chelates
Prior art date
Application number
EA201992595A
Other languages
English (en)
Inventor
Эрик Стивен Бурак
Стюарт Джеймс Махони
Райан Уэйн Симмс
Джон Фицморис Вэллиант
Original Assignee
Фьюжн Фармасьютикалс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фьюжн Фармасьютикалс Инк. filed Critical Фьюжн Фармасьютикалс Инк.
Publication of EA201992595A1 publication Critical patent/EA201992595A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к конъюгатам, содержащим хелатирующий фрагмент или его комплекс с металлом и терапевтический или нацеливающий фрагмент, способам их получения и их применению.
EA201992595A 2017-05-05 2018-05-04 Усиление фармакокинетики бифункциональных хелатов и их применения EA201992595A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762502260P 2017-05-05 2017-05-05
PCT/US2018/031228 WO2018204869A1 (en) 2017-05-05 2018-05-04 Pharmacokinetic enhancements of bifunctional chelates and uses thereof

Publications (1)

Publication Number Publication Date
EA201992595A1 true EA201992595A1 (ru) 2020-04-21

Family

ID=64016761

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992595A EA201992595A1 (ru) 2017-05-05 2018-05-04 Усиление фармакокинетики бифункциональных хелатов и их применения

Country Status (15)

Country Link
US (2) US11191854B2 (ru)
EP (1) EP3619191A4 (ru)
JP (2) JP2020518673A (ru)
KR (1) KR102612882B1 (ru)
CN (2) CN117603148A (ru)
AU (3) AU2018261888B2 (ru)
BR (1) BR112019023246B1 (ru)
CA (1) CA3062553C (ru)
CL (1) CL2019003168A1 (ru)
EA (1) EA201992595A1 (ru)
IL (1) IL270453B1 (ru)
MA (1) MA48861A (ru)
RU (1) RU2019139432A (ru)
WO (1) WO2018204869A1 (ru)
ZA (1) ZA201908071B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015073575A2 (en) * 2013-11-12 2015-05-21 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
KR102612882B1 (ko) 2017-05-05 2023-12-11 센터 포 프로브 디벨롭먼트 앤드 커머셜리제이션 이관능성 킬레이트 및 그의 용도의 약동학적 증진
KR20200004861A (ko) * 2017-05-05 2020-01-14 퓨전 파마슈티칼즈 인크. Igf-1r 모노클로날 항체 및 그의 용도
WO2020023092A2 (en) * 2018-04-25 2020-01-30 The Johns Hopkins University Alpha particle formulations for treatment of solid tumors
WO2019240884A2 (en) * 2018-04-27 2019-12-19 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
MA54399A (fr) * 2018-12-03 2021-10-13 Fusion Pharmaceuticals Inc Radioimmunoconjugués et polythérapie à base d'inhibiteur de point de contrôle
CN115243729A (zh) * 2020-01-10 2022-10-25 融合制药公司 大环螯合物及其用途
CA3167285A1 (en) * 2020-01-10 2021-07-15 Fusion Pharmaceuticals Inc. Sustained immunotherapy
BR112022019226A2 (pt) * 2020-03-23 2022-11-08 Fusion Pharmaceuticals Inc Radioimunoconjugados direcionados a fgfr3 e usos dos mesmos
KR102362962B1 (ko) * 2020-06-12 2022-02-16 (주)미래바이오팜 신규한 화합물 및 이를 함유하는 신경 손상, 신경 질환, 또는 발달 장애에 대한 신경세포의 증식 촉진, 분화, 및/또는 재생을 통한 치료 또는 예방용 약제학적 조성물
EP4190801A4 (en) * 2020-07-29 2024-10-02 Chugai Seiyaku Kabushiki Kaisha METHOD FOR MEASURING THE PHARMACOKINETICS OF A DRUG LABELED WITH A NON-RADIOACTIVE SUBSTANCE
WO2022198319A1 (en) * 2021-03-23 2022-09-29 Fusion Pharmaceuticals Inc. Use of a cold fgfr3-targeting molecule and a fgfr3 targeting radioimmunoconjugate for treating cancer
CN117836011A (zh) * 2021-06-17 2024-04-05 梅约医学教育与研究基金会 将生物制剂与多种螯合剂组合的方法和材料
WO2023164777A1 (en) * 2022-03-04 2023-09-07 Fusion Pharmaceuticals Inc. Gucy2c-targeted radiopharmaceuticals and use thereof
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
WO2024138060A2 (en) * 2022-12-21 2024-06-27 Mayo Foundation For Medical Education And Research Methods and materials for combining biologics with multiple chelators

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175343A (en) 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
DE3713842A1 (de) * 1987-04-22 1988-11-17 Schering Ag Substituierte cyclische komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US4889931A (en) 1988-09-27 1989-12-26 Salutar, Inc. Manganese (II) chelate manufacture
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0382583B1 (en) 1989-02-10 1996-01-17 Celltech Therapeutics Limited Aza macrocycles and processes for their preparation
US5053503A (en) 1989-02-17 1991-10-01 Centocor Chelating agents
US6274713B1 (en) 1989-04-07 2001-08-14 Salutar, Inc. Polychelants
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
BR9102490A (pt) 1990-06-18 1992-01-21 Dow Chemical Co Metodo para uso diagnostico na formacao de imagens e composicao
US5386011A (en) 1990-12-27 1995-01-31 Abbott Laboratories Hexapeptide anaphylatoxin-receptor ligands
GB9112536D0 (en) * 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DE69331319T2 (de) 1992-06-09 2002-08-08 Neorx Corp., Seattle Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren
US5358704A (en) 1993-09-30 1994-10-25 Bristol-Myers Squibb Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents
GB9504922D0 (en) 1995-03-10 1995-04-26 Nycomed As Process
DK0970126T3 (da) 1997-04-14 2001-08-13 Micromet Ag Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf
IT1291624B1 (it) 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
IT1304501B1 (it) 1998-12-23 2001-03-19 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza
JP2003501488A (ja) 1999-06-11 2003-01-14 ネオルックス コーポレイション 骨髄抑制のための高投与量放射性核種錯体
DE10002939C1 (de) 2000-01-13 2001-09-20 Schering Ag Paramagnetische DOTA-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung für die Herstellung von pharmazeutischen Mitteln
US20020052354A1 (en) 2000-01-27 2002-05-02 Schering Ag Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction
US6264966B1 (en) 2000-02-22 2001-07-24 Concat, Ltd. Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
ATE271396T1 (de) 2000-05-12 2004-08-15 Univ Hospital Prochelators von radiometall markierten molekülen
AU2002249935A1 (en) 2001-01-08 2002-08-19 Neorx Corporation Radioactively labelled conjugates of phosphonates
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
DE10135356C1 (de) 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
WO2004013161A2 (en) 2002-08-06 2004-02-12 Epix Pharmaceuticals, Inc. Peptide aggregates
DE10250870A1 (de) 2002-10-31 2004-05-13 Switch Biotech Ag Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung
WO2004071535A1 (en) 2003-02-13 2004-08-26 Bracco Imaging S.P.A. Contrast enhanced x-ray phase imaging
ATE410191T1 (de) * 2003-03-19 2008-10-15 Universitaetsspital Basel Auf substanz p basierende radiomarkierte konjugate und deren gebrauch
US20060155120A1 (en) 2003-05-23 2006-07-13 Amedio John C Optically pure and enriched isomers of chelating ligands and contrast agents
JP4262545B2 (ja) 2003-07-09 2009-05-13 三菱電機株式会社 カスコード接続回路及びその集積回路
DE602004025592D1 (de) 2003-09-12 2010-04-01 Life Technologies Corp Anwendungen des Resonanzenergietransfers zwischen Terbium und GFP
CN100528162C (zh) 2003-12-19 2009-08-19 先灵公司 药物组合物
WO2005079803A1 (en) 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
WO2006015318A2 (en) 2004-07-30 2006-02-09 Biogen Idec Inc. Antibody conjugated to a drug moiety via a poptidic linker
ES2669510T3 (es) 2004-09-23 2018-05-28 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US20060222595A1 (en) 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
UY29663A1 (es) 2005-07-15 2007-02-28 Schering Ag Complejos metalicos con contenido de perfluoroalquilo, procedimientos para su preparacion, así como su uso
US7618957B2 (en) 2005-07-15 2009-11-17 Bayer Schering Pharma Aktiengesellschaft Perfluoroalkyl-containing complexes, process for their production as well as their use
US20100226884A1 (en) * 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
US8034898B2 (en) 2005-12-29 2011-10-11 Collagen Medical, LLC Methods of collagen imaging
WO2007106544A2 (en) 2006-03-15 2007-09-20 Mallinckrodt Inc. Chelating conjugates having a substituted aromatic moiety and derivatives thereof
US7777029B2 (en) 2006-05-02 2010-08-17 San Diego State University (Sdsu) Foundation Bifunctional chelators for sequestering lanthanides
WO2008112008A2 (en) 2006-08-11 2008-09-18 Invitrogen Corporation Sensor proteins and assay methods
US8691761B2 (en) * 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
GB0624587D0 (en) 2006-12-08 2007-01-17 Univ Muenchen Tech Chelating agent
JP2010516679A (ja) * 2007-01-19 2010-05-20 マリンクロット インコーポレイテッド 診断用および治療用シクロオキシゲナーゼ−２結合リガンド
WO2008134289A2 (en) 2007-04-26 2008-11-06 Mallinckrodt Inc. High relaxivity coordinatively unsaturated lanthanide complexes
WO2009029464A1 (en) 2007-08-27 2009-03-05 Mallinckrodt Inc. Removal of silica from water soluble compounds by nanofiltration and reverse phase chromatography
JP2010537985A (ja) 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗ｉｇｆ−１ｒ抗体およびその使用
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
DE102008045937B4 (de) 2008-04-11 2017-01-26 Johannes-Gutenberg-Universität Mainz Radiopharmakon aus einem Metallion und einem Markierungsvorläufer und Verwendung des Radiopharmakons
WO2010009246A2 (en) 2008-07-16 2010-01-21 The General Hospital Corporation Methods and reagents for preparing multifunctional probes
EP2147684A1 (en) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
US20110319339A1 (en) 2008-11-06 2011-12-29 Luisa Bracci Neurotensin-derived branched peptides and uses thereof
WO2010088527A2 (en) 2009-01-30 2010-08-05 Mayo Foundation For Medical Education And Research Peptides and nanoparticles for therapeutic and diagnostic applications
CN102356087A (zh) 2009-03-19 2012-02-15 惠氏有限责任公司 [2-(8,9-二氧代-2,6-二氮杂双环[5.2.0]壬-1(7)-烯-2-基)乙基]膦酸及其前体的制备方法
WO2011005609A2 (en) 2009-07-08 2011-01-13 Mayo Foundation For Medical Education And Research Imaging gastrointestinal volumes and motility
CA2785410A1 (en) 2009-12-23 2011-06-30 Carlos F. Barbas, Iii Tyrosine bioconjugation through aqueous ene-like reactions
CA2787074A1 (en) 2010-01-19 2011-07-28 Immunomedics, Inc. Novel antibodies that target the insulin-like growth factor type i receptor (igf-1r)
EP2397466B1 (en) * 2010-06-15 2012-11-28 Centre National De La Recherche Scientifique CNRS X-ray and gamma-photon activatable organic compounds, their preparation and their uses
WO2012021796A2 (en) 2010-08-12 2012-02-16 S&T Global, Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
US12097269B2 (en) 2010-10-27 2024-09-24 Vikas Kundra Dual mode gadolinium nanoparticle contrast agents
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
DK2721045T3 (en) 2011-06-20 2017-07-24 Radiomedix Inc COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS
FR2976825B1 (fr) 2011-06-22 2014-02-21 Total Sa Nanotraceurs pour le marquage d'eaux d'injection de champs petroliers
EP2604281B1 (en) 2011-12-14 2014-07-30 Centre National de la Recherche Scientifique (CNRS) Clicked somatostatin conjugated analogs for biological applications
KR20130083592A (ko) 2012-01-13 2013-07-23 현대약품 주식회사 치환된 피페리딘 유도체 및 이의 제조방법
WO2013148568A1 (en) 2012-03-30 2013-10-03 Merck Sharp & Dohme Corp. Igf1 biomarker for igf1r inhibitor therapy
CN104603262A (zh) 2012-06-14 2015-05-06 詹森生物科技公司 使人胚胎干细胞分化为胰腺内分泌细胞
CN102743770B (zh) 2012-06-18 2017-07-21 申宝忠 一种靶向性分子成像探针及活体分子成像方法
EP2892570B1 (en) 2012-09-07 2019-02-27 Bracco Imaging S.p.A Paramagnetic solid lipid nanoparticles (pslns) containing metal amphiphilic complexes for mri
US9931412B2 (en) 2013-02-08 2018-04-03 The Regents Of The University Of Michigan Targeted theranostics
AU2014264973B2 (en) 2013-05-06 2018-01-18 Merck Patent Gmbh Macrocycles as kinase inhibitors
US10786497B2 (en) * 2013-08-16 2020-09-29 Equip, Llc Discrete PEG constructs
WO2015038968A1 (en) 2013-09-13 2015-03-19 The General Hospital Corporation Activatable fibrin-binding probes
EP4095130B1 (en) 2013-10-18 2024-01-31 Novartis AG Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015073575A2 (en) 2013-11-12 2015-05-21 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
WO2015085005A1 (en) 2013-12-03 2015-06-11 The General Hospital Corporation Molecular imaging probes
FR3015547B1 (fr) 2013-12-20 2016-01-01 Total Sa Methode pour ajuster le taux d'inhibiteurs dans un puits de petrole ou de gaz
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
AU2015243380B2 (en) 2014-04-11 2020-05-14 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
PT3134127T (pt) 2014-04-25 2020-04-09 Rinat Neuroscience Corp Conjugados de anticorpo-fármaco com alta carga de fármaco
WO2015176056A1 (en) * 2014-05-16 2015-11-19 Memorial Sloan Kettering Cancer Center One-step labeling of antibodies to high specific activity with actinium-225
US20180036442A1 (en) 2014-07-29 2018-02-08 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
BE1021191B1 (fr) 2014-08-29 2015-10-27 Anmi S.A. Kit pour radiomarquage.
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
DE102014115154A1 (de) 2014-10-17 2016-04-21 SCV-SpezialChemikalien-Vertrieb GmbH Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen
ES2981335T3 (es) 2014-11-25 2024-10-08 Bristol Myers Squibb Co Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
US20190015518A1 (en) * 2016-01-04 2019-01-17 University Of Kansas Drug delivery compositions and methods
WO2017161356A1 (en) * 2016-03-18 2017-09-21 Wake Forest University Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography
CN118368739A (zh) * 2017-03-24 2024-07-19 中兴通讯股份有限公司 一种无线资源配置方法、装置及用户设备、网络节点
US10093741B1 (en) * 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
KR102612882B1 (ko) 2017-05-05 2023-12-11 센터 포 프로브 디벨롭먼트 앤드 커머셜리제이션 이관능성 킬레이트 및 그의 용도의 약동학적 증진

Also Published As

Publication number Publication date
EP3619191A4 (en) 2020-12-16
WO2018204869A1 (en) 2018-11-08
CA3062553C (en) 2024-02-06
US11191854B2 (en) 2021-12-07
RU2019139432A3 (ru) 2021-06-16
EP3619191A1 (en) 2020-03-11
CN117603148A (zh) 2024-02-27
CN111263747A (zh) 2020-06-09
IL270453A (ru) 2020-12-31
ZA201908071B (en) 2023-04-26
RU2019139432A (ru) 2021-06-07
AU2018261888B2 (en) 2022-06-30
KR20200006087A (ko) 2020-01-17
BR112019023246B1 (pt) 2023-11-14
KR102612882B1 (ko) 2023-12-11
AU2018261888A1 (en) 2019-11-28
AU2024227706A1 (en) 2024-11-21
CN111263747B (zh) 2023-10-27
BR112019023246A8 (pt) 2021-02-23
AU2022221451A1 (en) 2022-09-22
JP2020518673A (ja) 2020-06-25
BR112019023246A2 (pt) 2020-05-19
CA3062553A1 (en) 2018-11-08
JP2023090748A (ja) 2023-06-29
IL270453B1 (en) 2025-01-01
CL2019003168A1 (es) 2020-08-28
US20190030194A1 (en) 2019-01-31
US20220054664A1 (en) 2022-02-24
MA48861A (fr) 2020-04-01

Similar Documents

Publication Publication Date Title
EA201992595A1 (ru) Усиление фармакокинетики бифункциональных хелатов и их применения
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
HK1259487A1 (zh) 特定的共軛連接子，特定的免疫共軛物，製造和使用這些共軛物的方法
JOP20190291A1 (ar) جزيئات جسم مضاد ضد cd73 واستخداماتها
MX2021008334A (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco.
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
MX2024006675A (es) Anticuerpos monoclonales del receptor del factor de crecimiento 1 tipo insulina (igf-1r) y usos de los mismos.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2018011204A (es) Conjugados de anticuerpo-farmaco dirigidos a napi2b y sus metodos de uso.
EA201800444A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
EA201401254A1 (ru) Самостабилизирующиеся линкерные конъюгаты
EA201792055A1 (ru) Антитела против cd48 и их конъюгаты
EA201992456A3 (ru) Самостабилизирующиеся линкерные конъюгаты
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
EA202091161A1 (ru) Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
MX2018005785A (es) Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
EA201990978A1 (ru) Антитела против pd-1
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
EA202090945A1 (ru) Анти-msln-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
MX2018000135A (es) Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2).
EA202193121A1 (ru) Лечение рака